These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 13194713)

  • 1. Combined use of ultraviolet irradiation and beta propiolactone sterilization of sera infected with a virus.
    SMOLENS J; STOKES J
    Proc Soc Exp Biol Med; 1954 Jul; 86(3):538-9. PubMed ID: 13194713
    [No Abstract]   [Full Text] [Related]  

  • 2. BETA-PROPIOLACTONE PLUS ULTRAVIOLET IRRADIATED PLASMA. A CLINICAL EVALUATION FOR HEPATITIS, TOXICITY AND ALLERGY.
    WOLFRAM BR; LOGRIPPO GA
    Bibl Haematol; 1964; 19():644-7. PubMed ID: 14267084
    [No Abstract]   [Full Text] [Related]  

  • 3. Inactivation of hepatitis viruses and HIV in plasma and plasma derivatives by treatment with beta-propiolactone/UV irradiation.
    Stephan W
    Curr Stud Hematol Blood Transfus; 1989; (56):122-7. PubMed ID: 2642784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Monitoring of sterilization procedures for plasma derivatives using bacteriophages].
    Dichtelmüller H; Stephan W
    Immun Infekt; 1988 Feb; 16(1):18-20. PubMed ID: 3283031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of combined treatment of serum containing hepatitis B virus with beta-propiolactone and ultraviolet irradiation.
    Stephan W; Berthold H; Prince AM
    Vox Sang; 1981 Sep; 41(3):134-8. PubMed ID: 7331286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The activity of human regains exposed to the disinfectant, beta-propiolactone.
    FLICK JA; FEINBERG RJ
    J Allergy; 1955 May; 26(3):262-7. PubMed ID: 14366906
    [No Abstract]   [Full Text] [Related]  

  • 7. Inactivation of hepatitis A virus added to pooled human plasma by beta-propiolactone treatment and ultraviolet irradiation.
    Frösner GG; Stephan W; Dichtelmüller H
    Eur J Clin Microbiol; 1983 Aug; 2(4):355-7. PubMed ID: 6313360
    [No Abstract]   [Full Text] [Related]  

  • 8. A TEN YEAR CLINICAL STUDY OF PLASMA TREATED WITH BETAPRONE AND COMBINED BETAPRONE PLUS ULTRAVIOLET IRRADIATION. COMPARISON WITH PRESENT METHODS OF TREATMENT.
    LOGRIPPO GA
    Pac Med Surg; 1964; 72():298-302. PubMed ID: 14208310
    [No Abstract]   [Full Text] [Related]  

  • 9. PROPIOLACTONE PLUS ULTRAVIOLET-TREATED PLASMA WITHOUT HEPATITIS. SIX YEARS' EXPERIENCE.
    LOGRIPPO GA; WOLFRAM BR; BRUSH BE
    Arch Surg; 1964 Apr; 88():721-4. PubMed ID: 14107028
    [No Abstract]   [Full Text] [Related]  

  • 10. HUMAN PLASMA TREATED WITH ULTRAVIOLET AND PROPIOLACTONE. SIX-YEAR CLINICAL EVALUATION.
    LOGRIPPO GA; WOLFRAM BR; RUPE CE
    JAMA; 1964 Mar; 187():722-6. PubMed ID: 14094292
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of beta-propiolactone, ultraviolet irradiation, and formalin on sendai virus cell-fusion factor.
    Pedreira FA; Tauraso NM
    Arch Gesamte Virusforsch; 1969; 28(3):361-8. PubMed ID: 4318620
    [No Abstract]   [Full Text] [Related]  

  • 12. Inactivation of non-A, non-B virus infectivity by a beta propiolactone/ultraviolet irradiation treatment and Aerosil adsorption procedure used for preparation of a stabilized human serum.
    Prince AM; Stephan W; Brotman B
    Vox Sang; 1984; 46(2):80-5. PubMed ID: 6322448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Biotest position on HIV-1 seroconversions in 1990 in 11 patients, treated with beta-propiolactone/uv virus inactivated PPSB].
    Pustoslemsek P; Kloft M; Kotitschke R
    Infusionsther Transfusionsmed; 1993 Dec; 20(6):344-6. PubMed ID: 8142739
    [No Abstract]   [Full Text] [Related]  

  • 14. Inactivation of hepatitis B and non-A, non-B viruses by combined use of Tween 80, beta-propiolactone, and ultraviolet irradiation.
    Prince AM; Stephan W; Kotitschke R; Brotman B
    Thromb Haemost; 1983 Aug; 50(2):534-6. PubMed ID: 6415846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The sterilization of human arterial homografts with beta-propiolactone; experimental and clinical observations.
    SZILAGYI DE; OVERHULSE PR; SHONNARD CP; LOGRIPPO GA
    Surg Forum; 1955; 5():244-52. PubMed ID: 13247029
    [No Abstract]   [Full Text] [Related]  

  • 16. Beta-propiolactone for the inactivation of non-A/non-B type 1 hepatitis virus capable of inducing cytoplasmic tubular ultrastructures in chimpanzees.
    Yoshizawa H; Itoh Y; Iwakiri S; Kitajima K; Noguchi Y; Tachibana K; Nakamura T; Miyakawa Y; Mayumi M
    Vox Sang; 1984; 46(2):86-91. PubMed ID: 6422638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virus safety of beta-propiolactone treated plasma preparations. Clinical experiences.
    Heinrich D; Sugg U; Brackmann HH; Stephan W; Lissner R
    Dev Biol Stand; 1987; 67():311-7. PubMed ID: 3649316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sterilized hepatitis B (surface) antigen for production of specific antisera.
    Stephan W; May G
    Vox Sang; 1976; 31(6):416-22. PubMed ID: 64018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Inactivation and antigenicity of poliomyelitis virus type 2 (MEF-1 strain) treated with beta-propiolactone].
    D'ALESSANDRO G; ODDO FG; INSERILLO G
    Riv Ist Sieroter Ital; 1956; 31(1):65-8. PubMed ID: 13337026
    [No Abstract]   [Full Text] [Related]  

  • 20. Management of an artery-graft bank; with special reference to sterilisation by beta-propiolactone.
    BARSON GJ; CRAWFORD N; RAINS AJ; SHARPE SH; SHREWSBURY JF
    Lancet; 1956 Oct; 271(6947):830-2. PubMed ID: 13368532
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.